ESTRO 2024 - Abstract Book

S582

Clinical - Breast

ESTRO 2024

Variable

InBody at baseline

InBody after exercise P value

Lean mass right arm 6.22(1.24)

6.33(1.20) 6.23(1.07) 4.93(0.94) 4.86(0.83) 3.05(0.57) 3.01(0.52) 1.89(0.37) 1.85(0.31) 0.39(0.01) 0.38(0.004) 0.38(0.002)

.4416 .3486 .4177 .3479 .3601 .3139 .4741 .4542 .9142 .4375 .4144

Lean mass left arm

6.11(1.14) 4.85(0.96) 4.76(0.88) 2.99(0.59) 2.94(0.55) 1.86(0.37) 1.82(0.33) 0.39(0.01) 0.38(0.004) 0.38(0.004)

TBW right arm TBW left arm ICW right arm

ICW left arm

ECW right arm

ECW left arm

ECW/TBW

ECW/TBW right arm ECW/TBW left arm

Conclusion:

In summary, the structured and intense weight training program implemented in this study did not result in worse lymphedema in breast cancer survivors, though significant improvement was seen in lean mass in the upper extremities. These data should help support further efforts to prescribe exercise during breast cancer treatment and survivorship.

Keywords: Exercise, Lymphedema, Edema Index,

1925

Digital Poster

Safety and survival outcomes of combining T-DM1 with intracranial RT: a single center experience.

Viola Salvestrini, Chiara Mattioli, Carlotta Becherini, Luca Visani, Isacco Desideri, Marianna Valzano, Daniela Greto, Emanuela Olmetto, Erika Scoccimarro, Monica Mangoni, Anna Peruzzi, Carolina Orsatti, Giulio Frosini, Ilaria Bonaparte, Luca Burchini, Icro Meattini, Lorenzo Livi

Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Purpose/Objective:

Over the past decades, the introduction of HER2- targeted therapy has significantly changed the treatment landscape of HER2- positive metastatic breast cancer (MBC). Despite the improvement of overall prognosis of HER2 positive MBC patients (pts), brain metastases develop in about 50% of advanced breast cancer pts. Radiotherapy (RT), either stereotactic radiosurgery (SRS) or whole brain radiotherapy, is the standard of care for brain metastases. Trastuzumab emtansine (T-DM1), an antibody drug conjugate, has demonstrated improved outcomes in both early and advanced breast cancer. However, there is currently a lack of data on the safety profile of combining T-DM1 with intracranial RT. In this single center experience, we aim to evaluate the safety and survival outcomes of combining intracranial RT with T-DM1 in MBC settings.